TrialEmerging microbes & infections2025
Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial.
Gang Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.